Cargando…
Eumycetoma causative agents are inhibited in vitro by luliconazole, lanoconazole and ravuconazole
INTRODUCTION: Eumycetoma is a subcutaneous mutilating disease that can be caused by many different fungi. Current treatment consists of prolonged itraconazole administration in combination with surgery. In many centres, due to their slow growth rate, the treatment for eumycetoma is often started bef...
Autores principales: | Nyuykonge, Bertrand, Lim, Wilson, van Amelsvoort, Lukas, Bonifaz, Alexandro, Fahal, Ahmed, Badali, Hamid, Abastabar, Mahdi, Verbon, Annelies, van de Sande, Wendy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321754/ https://www.ncbi.nlm.nih.gov/pubmed/35398930 http://dx.doi.org/10.1111/myc.13442 |
Ejemplares similares
-
Screening the pandemic response box identified benzimidazole carbamates, Olorofim and ravuconazole as promising drug candidates for the treatment of eumycetoma
por: Lim, Wilson, et al.
Publicado: (2022) -
Epidemiological cut‐off values for itraconazole and ravuconazole for Madurella mycetomatis, the most common causative agent of mycetoma
por: Nyuykonge, Bertrand, et al.
Publicado: (2022) -
Madurella mycetomatis grains within a eumycetoma lesion are clonal
por: Nyuykonge, Bertrand, et al.
Publicado: (2022) -
Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim
por: Lim, Wilson, et al.
Publicado: (2020) -
Madurella mycetomatis Is Highly Susceptible to Ravuconazole
por: Ahmed, Sarah Abdalla, et al.
Publicado: (2014)